文献速递肾小球疾病肾移植

狼疮肾炎维持期霉酚酸药代动力学与药物基因组学及临床相关性

Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

在88例稳定期狼疮肾炎维持治疗患者中,每6个月重复监测霉酚酸(MPA)血药浓度,评估其与12小时AUC及ABCC2、OATP、UGT基因单核苷酸多态性的关系。C12与AUC0-12相关,且与肾脏复发、感染和贫血相关;ABCC2 rs2273697 A/G与较低MPA暴露相关。

要点

  • MPA C12与AUC0-12相关,可用于维持期暴露监测。
  • C12与肾脏复发、感染和贫血相关,低C12见于复发,高C12见于感染。
  • ABCC2 rs2273697 A/G与较低MPA暴露相关。

核心结论

  • MPA C12与AUC0-12相关,并与肾脏复发、感染和贫血相关。
  • ABCC2 rs2273697 A/G与较低MPA暴露相关。

研究设计与样本

  • 在88例接受泼尼松龙和霉酚酸酯维持治疗的稳定期狼疮肾炎患者中,于给药后1、2、4、8、10和12小时(C1、C2、C4、C8、C10、C12)测定血MPA水平,每6个月重复。
  • 同时分析MPA暴露与ABCC2(rs2273697、rs3740066、rs717620、rs17222723)、OATP(rs7311358、rs4149117)和UGT(rs17863762、rs6714486、rs17868320、rs72551330)单核苷酸多态性的关系。

主要发现

  • C1、C2和C12分别为8.3±6.6、7.2±5.2和2.0±1.4 mg/L,均与AUC0-12相关(r=0.51、0.85和0.73;P=0.02、<0.001和<0.001)。
  • C12与血红蛋白、免疫球蛋白和白细胞水平呈负相关(P均<0.05)。
  • 96周内发生5次肾脏复发、11次感染和10次贫血(血红蛋白<10 g/dL),对应C12分别为1.3±0.5、4.3±2.6和2.9±1.5 mg/L;无上述并发症者分别为2.4±1.2、1.8±1.2和1.7±1.1 mg/L(P=0.041、<0.001和0.004)。
  • ABCC2 rs2273697 A/G与较低MPA暴露相关(1075.9±239.9 vs 1891.5±918.9 mgh/L per g/kg;P=0.003)。
  • OATP和UGT的单核苷酸多态性与MPA水平无关。

临床怎么用

  • 维持期可考虑监测MPA C12以评估暴露并与AUC0-12关联。
  • 关注C12与肾脏复发、感染和贫血的关联,低C12时警惕复发,高C12时警惕感染。
  • ABCC2 rs2273697 A/G携带者可能MPA暴露较低,需关注剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is little data on mycophenolic acid (MPA) pharmacokinetics and pharmacogenomics and optimal MPA exposure in lupus nephritis (LN) patients during long-term maintenance. METHODS: We measured blood MPA levels at 1, 2, 4, 8, 10 and 12-h post-dose (i.e. C1, C2, C4, C8, C10 and C12) in 88 stable LN patients receiving maintenance prednisolone and mycophenolate mofetil, repeated every 6 months. The relationship between MPA exposure and single nucleotide polymorphisms (SNPs) of adenosine triphosphate-binding cassette subfamily C member 2 (ABCC2; rs2273697, rs3740066, rs717620 and rs17222723), organic anion-transporting polypeptides (OATPs; rs7311358 and rs4149117) and uridine diphosphate glucuronosyltransferase (UGT; rs17863762, rs6714486, rs17868320 and rs72551330) was also investigated. RESULTS: C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively). C12 inversely correlated with hemoglobin, immunoglobulins and leukocyte levels (P < 0.05 for all). Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004). SNP rs2273697 A/G in the ABCC2 gene was associated with lower MPA exposure compared with G/G (1075.9 ± 239.9 versus 1891.5 ± 918.9 mgh/L per g/kg; P = 0.003). SNPs of OATP and UGT were unrelated to MPA level. CONCLUSION: MPA C12 correlates with the AUC0-12 and is related to renal flare, infection and anemia. SNP rs2273697 A/G is associated with lower MPA exposure.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yap DYH, Tam CH, Yung S, et al. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrol Dial Transplant. 2020. PMID: 30215770. doi:10.1093/ndt/gfy284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。